anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE OF REVIEW: The literature was reviewed for all noninvasive central nervous system (CNS) stimulation techniques, which includes transcranial brain or trans-spinal stimulation, in the aging population. Given the rising ubiquity of this technology, noninvasive nature, and low side-effect profile reported, this technology can have a big impact on the aging population. As patients afflicted with neurogenic disorders are living longer lives, a special emphasis is placed on the aging neurogenic population.
RECENT FINDINGS: Noninvasive CNS stimulation techniques have been applied to major bladder and pelvic floor disorders such as voiding dysfunction, chronic pelvic pain, urgency and urge incontinence, lower urinary tract dysfunction, and situational urge incontinence in both the idiopathic and neurogenic populations. Overall, these noninvasive technologies demonstrate effectiveness for the treatment of these conditions with some studies showing effectiveness with longer-term follow-up suggesting lasting CNS remodeling.
SUMMARY: Most manuscripts had a generally small number of patients and an even smaller number of geriatric patients represented. No studies were specifically designed to investigate geriatric outcomes. It is the hope of this systematic review to help model future studies according to existing literature, but with a focus on the geriatric population as they stand to gain the most from noninvasive technologies with limited adverse events.
PURPOSE:The titled bathing agent capable of being subjected to automatic separating packaging of volumetric or gravimetric type, not separating dried leaves of Artemisia vulgaris var. vulgatissima and A. vulgaris var indica from other crude drugs, obtained by blending them with a binder consisting of an alcohol or liquid perfume and a dispersant for the dried leaves such as sodium chloride, borax, etc. CONSTITUTION:Powdered dried leaves of Artemisia vulgaris var. vulgatissima and A. vulgaris var. indica as a main agent is blended with other powder crude drug (e.g., ginder, Licorice, Aurantii Nobilis Pericarpium, sweet-flag), 10-50pts.wt. based on 100pts.wt. of the powdered leaves of a binder consisting of an alcohol (monohydric alcohol which is preferably blended with a polyhydric alcohol in order to adjust viscosity) or liquid perfume and 3-7 times as much a dispersant selected from sodium hydrogencarbonate, sodium chloride, borax, sodium sesquicarbonate, sodium thiosulfate, salicylic acid(salicylate), potassium chloride, boric acid as the dried leaves by weight. Preferably the crude drugs other than the dried leaves are blended well, mixed with the dried leaves, and blended with the binder, and the dispersant in this order.
PROBLEM TO BE SOLVED: To obtain the subject composition good in smell and taste, excellent in foamability, low in irritability, not causing the change of palate and useful for tooth pastes, etc., by compounding a specific amidocarboxylic acid or its salt. SOLUTION: This composition contains an amidocarboxylic acid of formula III (R1 is a 8-22C alkyl, etc.; R2 is H, a 1-6C alkyl, etc.; R3 is a group of formula IV, etc.; M is H, an alkali metal, etc.), or its salt (mono-N-laurylmalic acid amide, etc.), in an amount of 0.05-20 wt.%, preferably 0.1-5 wt.%, based on the whole composition. The compound of formula III is obtained from inexpensive raw materials at a good yield by reacting an amine of formula I (octylamine, etc.), with a dicarboxylic acid (malic acid, etc.), in the absence of a catalyst or in the presence of a basic catalyst in a solvent-free state or in a proper solvent.
FIELD: pharmacy. SUBSTANCE: composition has allylamine compound as free base or acid salt at amount 0.5-30% of composition mass as an active component. Composition has also filling agents and polymeric film-forming substance at its ratio to allylamine compound = (0.5:1)-(25:1), respectively. Composition has polyvinyl acetate or copolymer of acrylic and methacrylic acid alkyl esters, or copolymer of maleic acid methylvinyl ester and monoalkyl ester as polymeric film-forming substance. Composition shows antifungal effect and can be used as nail lacquer. EFFECT: enhanced effectiveness of composition. 8 cl
The invention discloses a system and a computer storage medium for classifying non-alcoholic fatty liver disease patients. The research of the invention finds that the liver ultrasonic attenuation coefficient of a patient with nonalcoholic steatohepatitis (NASH) is obviously higher than that of a patient with nonalcoholic fatty liver disease (NAFL). Further research shows that the liver ultrasonic attenuation coefficient is related to the ballooning degree and the intersomental inflammation degree of nonalcoholic fatty liver disease (NAFLD) patients and SAS scoring. And the three are important parameters for calculating the NASH grade. These data indicate that the liver ultrasound attenuation coefficient can be used to assess whether NAFLD patients progress to NASH. Further, the liver ultrasonic attenuation coefficient can be used as an effective index for judging the NASH patient. Considering that the presence of NASH is a poor prognostic course of NAFLD and that there is currently a lack of effective non-invasive assessment means, the potential role of hepatic ultrasound attenuation coefficient in assessing NASH is of great clinical significance.
Control of the global HIV pandemic will require the development of a safe and effective vaccine. Many HIV preventive vaccines that are in development use a recombinant adenovirus serotype 5 (rAd5) vector as a way of delivering the vaccine into cells. However, the majority of people, particularly in the developing world, have immunity against the Ad5 vector, which means the vaccine will not be effective at preventing HIV infection. This study will use a rAd26 vector as part of a HIV vaccine, as research has shown that relatively few people have immunity against this vector. The purpose of this study is to evaluate the safety and immunogenicity of a rAd26 vector preventive HIV-1 vaccine.

This study will enroll healthy, HIV-uninfected people. Participants will be randomly assigned to receive either the rAd26 vaccine or a placebo vaccine. All vaccines will be injected into the upper arm. At the vaccination study visit, participants will undergo a medical and medication history review, physical examination, and a rectal sampling procedure. They will then receive their assigned vaccine. After receiving the vaccine, participants will remain in the clinic for at least 30 minutes for observation and monitoring of side effects. Participants will receive counseling on HIV risk reduction and pregnancy prevention. For 7 days after the vaccination, participants will monitor their temperature and side effects. Additional study visits will occur at Days 1, 3, 7, 14, 28, 61, 168, and 365. At these visits, participants will undergo a medical history review, physical examination, counseling, and blood collection. At the Day 14 and 168 visits, a rectal sampling procedure will be performed. Participants will attend a study visit or be contacted by study researchers by telephone or e-mail 18 months after receiving the vaccine for follow-up health and safety monitoring. Participants may elect to attend optional follow-up visits for blood collection at Years 2, 3, 4, and 5.
PURPOSE: A solid dispersion containing 20-O-beta-D-glucopyranosyl-20(S)-protopanaxadiol and saturated polyglycolated glyceride is provided. CONSTITUTION: A solid dispersion contains 20-O-beta-D-glucopyranosyl-20(S)-protopanaxadio as a pharmacologically active ingredient and saturated polyglycosylated glyceride as a lipid matrix. The saturated polyglycolated glyceride is a mixture of mono-, di- and tri-glyceride and polyethylene glyceride and mono- and di-ester of polyethylene glycol. The solid dispersion is a capsule. A pharmaceutical formulation contains the solid dispersion and pharmaceutically acceptable additive. The formulation is a capsule or table.
The use of conventional chemotherapy in conjunction with targeted and immunotherapy drugs has emerged as an option to limit the severity of side effects in patients diagnosed with head and neck cancer (HNC), particularly oropharyngeal cancer (OPC). OPC prevalence has increased exponentially in the past 30 years due to the prevalence of human papillomavirus (HPV) infection. This study reports a comprehensive review of clinical trials registered in public databases and reported in the literature (PubMed/Medline, Scopus, and ISI web of science databases). Of the 55 clinical trials identified, the majority (83.3%) were conducted after 2015, of which 77.7% were performed in the United States alone. Eight drugs have been approved by the FDA for HNC, including both generic and commercial forms: bleomycin sulfate, cetuximab (Erbitux), docetaxel (Taxotere), hydroxyurea (Hydrea), pembrolizumab (Keytruda), loqtorzi (Toripalimab-tpzi), methotrexate sodium (Trexall), and nivolumab (Opdivo). The most common drugs to treat HPV-associated OPC under these clinical trials and implemented as well for HPV-negative HNC include cisplatin, nivolumab, cetuximab, paclitaxel, pembrolizumab, 5-fluorouracil, and docetaxel. Few studies have highlighted the necessity for new drugs specifically tailored to patients with HPV-associated OPC, where molecular mechanisms and clinical prognosis are distinct from HPV-negative tumors. In this context, we identified most mutated genes found in HPV-associated OPC that can represent potential targets for drug development. These include TP53, PIK3CA, PTEN, NOTCH1, RB1, FAT1, FBXW7, HRAS, KRAS, and CDKN2A.
The patients who are randomly allocated to this arm will receive a drink composed of anhydrous beet dextrose in water (200g/L). They will sip the drink for 4 hours of the 6 hour study.
The invention belongs to the field of biomedicine, and relates to preparation and application of a fucoidan gemcitabine liposome targeting pancreatic cancer. The invention solves the problem of providing a nanoparticle capable of targeting and effectively treating pancreatic cancer. The specific preparation steps of the targeting nanoparticle are as follows: 1) the fucoidan with proper molecular weight and negative charge is obtained by decoloring, ion exchange chromatography, concentration, dialysis and freeze-drying. 2) Gemcitabine cationic liposomes were prepared by ethanol injection using DOTAP, DMPC, Chol, DSPE-PEG2000 in a molar ratio of 1: 0.1. 3) The fucoidan is wrapped on the outer layer of the cationic liposome by electrostatic self-assembly. The nanoparticle prepared by the invention has a good inhibition effect on pancreatic cancer cell growth, and is a novel carrier for realizing targeted therapy of pancreatic cancer.
GSK2118436 (4 capsules of 75 mg) will be administered orally at the dose of 300 mg BID from Day 1 to 7 (and single dose on Day 8) under fasted conditions, either 1 hour before or 2 hours after a meal. If 225 mg BID is not tolerated in Part 1 /Cohort 1, then Part 1/Cohort 2 will not be initiated and 150 mg BID will be used in Part 2.
PURPOSE:To obtain the titled composition having a specific melting point and giving flowable hair, by compounding waxes (e.g. Japan wax or beeswax), a higher alcohol and a cationic or anionic surfactant at specific ratios, wherein the sum of the above components accounts for a specific ratio in the whole composition. CONSTITUTION:The titled hair-conditioning composition contains (A) one or more waxes selected from candelilla wax, rice wax, cotton wax, ceresin, hardened castor oil, etc., (B) one or more kinds of higher alcohols and (C) a cationic surfactant or an anionic surfactant. The amounts of the components A, B and C are 20-55wt.%, 10-60wt.% and 5-30wt.%, respectively and the sum of the 3 components is 3-75wt.% based on the whole composition. The melting point of the mixture is 40-90 deg.C. The composition is free from stickiness and is capable of simultaneously imparting the hair with flowability, smoothness and bindability.
INTRODUCTION: The presence of ureteral stones can cause pain, infections of urinary tract and hydronephrosis, resulting in the loss of renal function. For two decades, Ureteroscopy and laser stone fragmentation (URSL) attained a big rise and is the first line management for large ureteric stones and renal stones up to 2 cm. The present study was conducted to assess the success rate of ureteroscopic lithotripsy in treatment of ureteric calculus after local administration of aminophylline.
MATERIALS AND METHODS: 100 patients having ureteric calculi <20 mm in size, aged 20-60 years were included in the study and randomly divided into Group A (n = 50) with administration of local aminophylline and Group B (n = 50) with administration of saline infusion. Ureteroscopy was performed after 5 min of administration of the solution. URSL was done using pneumatic lithoclast and/or laser. Various parameters like duration of procedure, ease of ureteral access, requirement of DJ Stent and need of further operative interventions were compared between case and control groups. The data was collected and then subjected to statistical analysis using IBM SPSS 20.0 version at significance level of p < 0.05.
RESULTS: The mean age of study subjects having ureteral stones was found to be between 31 and 40 years of age with males being more affected. We observed less mean duration of surgery, higher success rate, easy ureteral access (p-value < 0.05) with aminophylline use than control group. The need of ureteral stent and Auxiliary procedures was significantly higher in the control than in the case group (38%).
CONCLUSION: The use of aminophylline has been found to be highly useful and effective in reducing the need of stents and secondary surgery, decreased pain, and increased success rate. Thus, the use of aminophylline is recommended during URSL procedure for the successful management of ureteral calculi.
For virtual reality training, the Pablo system was utilized. In both one- and two-dimensional modules, it is a game-based kind of rehabilitation. Based on the concepts of motor learning, this apparatus is used to train users. Using sensors to operate the games, the Pablo system features several boards, multiball, and handheld devices. The virtual reality program consisted of 45 minutes provided three times a week for three months.
Horticultural practices, consisting of 6 sessions with a one-week interval,was applied face to face to this intervention group. Each session lasted approximately 60 minutes.
<P>PROBLEM TO BE SOLVED: To obtain an excellent skin wrinkle improving cosmetic composition effective for suppressing collagenase activity.  <P>SOLUTION: This skin wrinkle improving cosmetic composition contains an extract of Bergenia emeiensis which is a perennial herb belonging to the family Saxifragaceae. The Bergenia emeiensis extract exhibits excellent inhibiting action on elastase and collagenase. The extract is extracted with water, an alcohol, an organic solvent, or the like. The skin wrinkle improving cosmetic composition containing the Bergenia emeiensis extract has high inhibiting action on elastase and collagenase and develops excellent skin wrinkle improving effect.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
Participants will receive a total of 24 milligrams (mg) of recombinant t-PA infusion, at an infusion rate of 1 milligrams/hour (mg/hr) per device (2 mg/hour for bilateral PE) delivered through the EkoSonic® Endovascular System. This regimen allows for a recombinant t-PA infusion time of 24 hours for one catheter and 12 hours for two catheters, respectively.
The present invention discloses a tablet rapidly disintegrated in the oral cavity, and is made from traditional Chinese medicine or natural medicinal substances. The present invention comprises: the active ingredients of the traditional Chinese medicine or the natural medicinal substances, or extractives containing active ingredients, and auxiliary materials suitable for pharmacy. The active ingredients of the traditional Chinese medicine or the natural medicinal substances are effective mono-meric compound extracted and separated from the traditional Chinese medicine or natural medicinal plants. The extractives containing active ingredients are extracted from single traditional Chinese medicine, or natural medicinal plants, or compound traditional Chinese medicine, or compound natural medicinal plants. The present invention has the advantages of good rapid disintegration and good rapid dissolution. The tablet is put in the oral cavity, and is disintegrated within 40 seconds without water. Users have no foreign matter sense and no sand sense in the mouth. The time of drug dissolution is less than 15 minutes. The present invention can be industrially produced by universal tabletting apparatuses, has high mechanical strength and good abrasion resistance, can not be crushed when the present invention is packaged, transported and taken, and keeps good appearance all the time.
PROBLEM TO BE SOLVED: To obtain a new DNA for producing a protein having activity of supporting or promoting differentiation and maturation of osteoclast, useful for a medicine for treating bone dysbolism, a reagent for study, etc., comprising a genome DNA encoding the protein. SOLUTION: This new genome DNA encodes a protein having the following physicochemical properties. Affinity: specifically combining with an osteoclastogenesis inhibitory factor(OCIF), having a high affinity (dissociation constant on a cell membrane, kd value is <=10-9). Molecular weight: about 30,000-40,000 by molecular weight measurement by SDS polyacrylamide electrophoresis under a nonreducing condition. Bioactivity: having activity of supporting or promoting differentiation or maturation of osteoclast by coculture of mouse osteoblast-like stroma cell and mouse splenocyte in the presence of bone resorption promoting factor such as activated vitamin D3 and parathormone, etc. The genome DNA is useful as a prophylactic and a therapeutic agent for bone dysbolism such as osteoporosis, etc.
Pancreatic cancer remains one of the most aggressive and lethal malignancies worldwide, with a dismal 5-year relative survival rates of only 12%. Therefore, it is urgent to discover the key molecular markers to improve the therapeutic outcomes in pancreatic cancer. Herein, we first demonstrated that PPM1G is upregulated in pancreatic cancer and that PPM1G depletion decreases pancreatic cancer cell growth in vitro and in vivo. High PPM1G expression was linked to short overall survival of pancreatic cancer patients, which was further validated in the TCGA database. Moreover, by detecting Beclin 1, LC3-II, and SQSTM1/p62 expressions and observing autolysosome under transmission electron microscope, we discovered that PPM1G is a novel positive regulator of macroautophagy/autophagy. Furthermore, by using immunoprecipitation-mass spectrometry (IP-MS) analysis and following systemic molecular biology experiment, we demonstrated PPM1G promotes the autophagy and proliferation of pancreatic cancer by directly upregulating HMGB1. Additionally, patients with both high PPM1G and high HMGB1 exhibited poorer prognosis in our cohort. This study preliminarily investigated the possibility of PPM1G as a potential therapeutic target and prognostic biomarker in pancreatic cancer patients.
A multi-component behavioral intervention to support family caregivers of persons with dementia. Participants will receive 4-6 sessions in-person or by phone over the course of 2-3 months.
WB-MRA is an examination that can evaluate the arteries from head to feet. Timing of the injected bolus of contrast medium can be difficult, especially in the legs. As the result of the WB-MRA depends on the contrast medium only being in the arteries at the time of examination, the use of venous compression is a possible way of overcoming the problem of early venous filling, that can hamper the diagnostic value of the examination. Venous compression is performed with a blod pressure cuff around the thighs. It is inflated to subsystolic pressure (45 mm Hg). This elevated pressure leads to filling of the lower leg arteries and late venous filling.
Twenty statistically matched patients (15 males, 5 females, aged between 28 and 70 years, median 50 years) with moderate to severe psoriasis (PASI: 7-36) were included in this study. They were treated with 15 mg alefacept i.m. weekly. Peripheral blood was taken prior to first alefacept application and then weekly until week five and thereafter every second week, until the end of treatment at week 13. At the same time points severity of disease and thereby possible reduction of symptoms was evaluated applying the PASI. Investigators analysing the samples were blinded to the outcome of the study. The protocol concerning human subjects was approved by the ethics commission of the Charité University Medicine Berlin Campus Mitte, Germany .
Folate: Allergic sensitizations have been reported following both oral and parenteral administration of folate.

Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation) occur occasionally but are usually mild and may subside with continuation of therapy. Although the absorption of iron is best when taken between meals, giving Prenatol-M™ after meals may control occasional gastrointestinal disturbances.  Prenatol-M™ is best absorbed when taken at bedtime. 

Adverse reactions have been reported with specific vitamins and minerals but generally at levels substantially higher than those contained herein. However, allergic, and idiosyncratic reactions are possible at lower levels. Iron, even at the usual recommended levels, has been associated with gastrointestinal intolerance in some patients.
PURPOSE: A sustained release formulation containing donepezil or pharmaceutically acceptable salt thereof is provided to effectively control release speed of donepezil or salt and to improve elusion safety. CONSTITUTION: A sustained release pharmaceutical composition contains donepezil or pharmaceutically acceptable salt thereof, and polyvinyl acetate or fatty acid ester. The salt is donepezil hydrochlorie. The polyvinyl acetate contains polyvinyl pyrrolidone and polyvinyl acetate in a weight ratio of 8:1~2. The fatty acid ester is glyceryl behenate, hydrogenated castor oil, stearyl, cetostearyl or cetyl alcohol, mono-, di, or tri glyceride, or solid paraffin. The composition additionally contains elution controlling agent such as carboxy methyl ethyl cellulose or methacrylic acid-acrylic acid ethyl copolymers. The composition also contains pharmaceutically acceptable additives. The composition is used for preventing and treating Alzheimer's disease. [Reference numerals] (AA) Embodiment 1; (BB) No added; (CC) Polystyrene bead; (DD) Oil; (EE) Pepsin
Once the MTD and/or RD has been determined in Phase 1A, an expansion cohort will be enrolled in order to characterize the safety, PK and preliminary clinical activity of ETC-1907206 in combination with dasatinib. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, withdrawal of consent or it is judged not to be in the patient's interest to continue on the study.
Laser Interstitial Thermal Therapy (LITT) - An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.